The DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index.
Vaccines for established cancer: overcoming the challenges posed by immune evasion
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Mellman, I., & Steinman, R. M. (2001) · Cell · doi:10.1016/s0092-8674(01)00449-4 · Cited by 2,237
Distinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Self-citationCTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
The role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3156 · Cited by 1,657
Schwartz, R. H. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141110 · Cited by 1,487
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Royal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,257
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Immunity to Methylcholanthrene-Induced Sarcomas
(1957) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/18.6.769 · Cited by 1,229
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Self-citationVaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Lowik, M. J. G., Berends-van der Meer, D. M. A., Vloon, A. P. G., Essahsah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810097 · Cited by 1,102
Self-citationRobbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037
Klebanoff, C. A., Gattinoni, L., Torabi-Parizi, P., Kerstann, K., Cardones, A. R., Finkelstein, S. E., Palmer, D. C., Antony, P. A., Hwang, S. T., Rosenberg, S. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503726102 · Cited by 969
Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P., & Ostrand-Rosenberg, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2587 · Cited by 949
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription Factor
Marigo, I., Bosio, E., Solito, S., Mesa, C., Fernandez, A., Dolcetti, L., Ugel, S., Sonda, N., Bicciato, S., Falisi, E., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.010 · Cited by 850
Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., Mitchell, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6963 · Cited by 815
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
“Re-educating” tumor-associated macrophages by targeting NF-κB
Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080108 · Cited by 792
Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.-Y., Mendrzyk, R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2883 · Cited by 788
Therapeutic vaccines for cancer: an overview of clinical trials
Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.111 · Cited by 776
Duraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 745
Trimble, C. L., Morrow, M. P., Kraynyak, K. A., Shen, X., Dallas, M., Yan, J., Edwards, L., Parker, R. L., Denny, L., Giffear, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00239-1 · Cited by 727
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Fu, J., Kanne, D. B., Leong, M., Glickman, L. H., McWhirter, S. M., Lemmens, E., Mechette, K., Leong, J. J., Lauer, P., Liu, W., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4306 · Cited by 720
Linnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 679
Self-citationStructure and Function of Toll Receptors and Their Ligands
Gay, N. J., & Gangloff, M. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.060305.151318 · Cited by 667
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3973 · Cited by 637
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
Landsberg, J., Kohlmeyer, J., Renn, M., Bald, T., Rogava, M., Cron, M., Fatho, M., Lennerz, V., Wölfel, T., Hölzel, M., et al. (2012) · Nature · doi:10.1038/nature11538 · Cited by 632
In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine
Deres, K., Schild, H., Wiesmüller, K.-H., Jung, G., & Rammensee, H.-G. (1989) · Nature · doi:10.1038/342561a0 · Cited by 631
The interaction of anticancer therapies with tumor-associated macrophages
Mantovani, A., & Allavena, P. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150295 · Cited by 616
Deciphering and Reversing Tumor Immune Suppression
Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 598
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
Melief, C. J. M., & van der Burg, S. H. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2373 · Cited by 594
Self-citationGoing viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Meyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., & Speiser, D. E. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1508-5 · Cited by 560
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
Mitchell, D. A., Batich, K. A., Gunn, M. D., Huang, M.-N., Sanchez-Perez, L., Nair, S. K., Congdon, K. L., Reap, E. A., Archer, G. E., Desjardins, A., et al. (2015) · Nature · doi:10.1038/nature14320 · Cited by 531
An IFN-γ–induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I–presented peptides
Saric, T., Chang, S.-C., Hattori, A., York, I. A., Markant, S., Rock, K. L., Tsujimoto, M., & Goldberg, A. L. (2002) · Nature Immunology · doi:10.1038/ni859 · Cited by 528
Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., Restifo, N. P., & Zanovello, P. (2000) · Blood · doi:10.1182/blood.v96.12.3838 · Cited by 527
CD8 + T‐cell memory in tumor immunology and immunotherapy
Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00391.x · Cited by 511
STING and the innate immune response to nucleic acids in the cytosol
Burdette, D. L., & Vance, R. E. (2013) · Nature Immunology · doi:10.1038/ni.2491 · Cited by 501
Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0733 · Cited by 500
Nowak, A. K., Lake, R. A., Marzo, A. L., Scott, B., Heath, W. R., Collins, E. J., Frelinger, J. A., & Robinson, B. W. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4905 · Cited by 463
Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T., Cho, H.-I., Antonia, S., Altiok, S., Celis, E., & Gabrilovich, D. I. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40269 · Cited by 460
Clinical targeting of the TNF and TNFR superfamilies
Croft, M., Benedict, C. A., & Ware, C. F. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3930 · Cited by 456
Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444
Bos, R., & Sherman, L. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1322 · Cited by 443
Ma, J., Liu, L., Che, G., Yu, N., Dai, F., & You, Z. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-112 · Cited by 437
Zwaveling, S., Mota, S. C. F., Nouta, J., Johnson, M., Lipford, G. B., Offringa, R., van der Burg, S. H., & Melief, C. J. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.350 · Cited by 417
Self-citationCD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes
Nelson, B. H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001323 · Cited by 416
Piersma, S. J., Jordanova, E. S., van Poelgeest, M. I. E., Kwappenberg, K. M. C., van der Hulst, J. M., Drijfhout, J. W., Melief, C. J. M., Kenter, G. G., Fleuren, G. J., Offringa, R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3388 · Cited by 414
Self-citationRegulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy
Colombo, M. P., & Piconese, S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2250 · Cited by 407
Soares, K. C., Rucki, A. A., Wu, A. A., Olino, K., Xiao, Q., Chai, Y., Wamwea, A., Bigelow, E., Lutz, E., Liu, L., et al. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000062 · Cited by 398
Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
Coward, J., Kulbe, H., Chakravarty, P., Leader, D., Vassileva, V., Leinster, D. A., Thompson, R., Schioppa, T., Nemeth, J., Vermeulen, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0945 · Cited by 390
In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor
Boissonnas, A., Fetler, L., Zeelenberg, I. S., Hugues, S., & Amigorena, S. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061890 · Cited by 377
Heusinkveld, M., de Vos van Steenwijk, P. J., Goedemans, R., Ramwadhdoebe, T. H., Gorter, A., Welters, M. J. P., van Hall, T., & van der Burg, S. H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100889 · Cited by 368
Self-citationvan den Eertwegh, A. J., Versluis, J., van den Berg, H. P., Santegoets, S. J., van Moorselaar, R. J. A., van der Sluis, T. M., Gall, H. E., Harding, T. C., Jooss, K., Lowy, I., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70007-4 · Cited by 357
Dijkgraaf, E. M., Heusinkveld, M., Tummers, B., Vogelpoel, L. T. C., Goedemans, R., Jha, V., Nortier, J. W. R., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3542 · Cited by 346
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
Kerkar, S. P., Goldszmid, R. S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58814 · Cited by 342
Rech, A. J., Mick, R., Martin, S., Recio, A., Aqui, N. A., Powell, D. J., Colligon, T. A., Trosko, J. A., Leinbach, L. I., Pletcher, C. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003330 · Cited by 337
Immunologic Parameters of Ultraviolet Carcinogenesis 2
Kripke, M. L., & Fisher, M. S. (1976) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/57.1.211 · Cited by 332
Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein
Medema, J. P., de Jong, J., van Hall, T., Melief, C. J. M., & Offringa, R. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.7.1033 · Cited by 330
Self-citationCombining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
Tang, C., Wang, X., Soh, H., Seyedin, S., Cortez, M. A., Krishnan, S., Massarelli, E., Hong, D., Naing, A., Diab, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0069 · Cited by 322
Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer
Donnem, T., Hald, S. M., Paulsen, E.-E., Richardsen, E., Al-Saad, S., Kilvaer, T. K., Brustugun, O. T., Helland, A., Lund-Iversen, M., Poehl, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1905 · Cited by 312
van Elsas, A., Sutmuller, R. P. M., Hurwitz, A. A., Ziskin, J., Villasenor, J., Medema, J.-P., Overwijk, W. W., Restifo, N. P., Melief, C. J. M., Offringa, R., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.481 · Cited by 309
Self-citationOhri, C. M., Shikotra, A., Green, R. H., Waller, D. A., & Bradding, P. (2009) · European Respiratory Journal · doi:10.1183/09031936.00065708 · Cited by 296
Arlen, P. M., Gulley, J. L., Parker, C., Skarupa, L., Pazdur, M., Panicali, D., Beetham, P., Tsang, K. Y., Grosenbach, D. W., Feldman, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2059 · Cited by 287
Costimulatory and coinhibitory receptors in anti‐tumor immunity
Driessens, G., Kline, J., & Gajewski, T. F. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00771.x · Cited by 286
Koopman, L. A., Corver, W. E., van der Slik, A. R., Giphart, M. J., & Fleuren, G. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.6.961 · Cited by 279
Garrido, F., Cabrera, T., & Aptsiauri, N. (2010) · International Journal of Cancer · doi:10.1002/ijc.25270 · Cited by 276
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
Zhou, G., Drake, C. G., & Levitsky, H. I. (2006) · Blood · doi:10.1182/blood-2005-07-2737 · Cited by 272
Czerniecki, B. J., Koski, G. K., Koldovsky, U., Xu, S., Cohen, P. A., Mick, R., Nisenbaum, H., Pasha, T., Xu, M., Fox, K. R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4038 · Cited by 266
Kimura, T., McKolanis, J. R., Dzubinski, L. A., Islam, K., Potter, D. M., Salazar, A. M., Schoen, R. E., & Finn, O. J. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0275 · Cited by 263
Thymic B Cells Are Licensed to Present Self Antigens for Central T Cell Tolerance Induction
Yamano, T., Nedjic, J., Hinterberger, M., Steinert, M., Koser, S., Pinto, S., Gerdes, N., Lutgens, E., Ishimaru, N., Busslinger, M., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.013 · Cited by 260
Pozzi, L.-A. M., Maciaszek, J. W., & Rock, K. L. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2071 · Cited by 259
Daayana, S., Elkord, E., Winters, U., Pawlita, M., Roden, R., Stern, P. L., & Kitchener, H. C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605611 · Cited by 252
Sevko, A., Michels, T., Vrohlings, M., Umansky, L., Beckhove, P., Kato, M., Shurin, G. V., Shurin, M. R., & Umansky, V. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202781 · Cited by 246
Welters, M. J. P., Kenter, G. G., de Vos van Steenwijk, P. J., Löwik, M. J. G., Berends-van der Meer, D. M. A., Essahsah, F., Stynenbosch, L. F. M., Vloon, A. P. G., Ramwadhdoebe, T. H., Piersma, S. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006500107 · Cited by 239
Self-citationEmens, L. A., Asquith, J. M., Leatherman, J. M., Kobrin, B. J., Petrik, S., Laiko, M., Levi, J., Daphtary, M. M., Biedrzycki, B., Wolff, A. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3494 · Cited by 236
Rittig, S. M., Haentschel, M., Weimer, K. J., Heine, A., Muller, M. R., Brugger, W., Horger, M. S., Maksimovic, O., Stenzl, A., Hoerr, I., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.289 · Cited by 226
van der Burg, S. H., Piersma, S. J., de Jong, A., van der Hulst, J. M., Kwappenberg, K. M. C., van den Hende, M., Welters, M. J. P., Van Rood, J. J., Fleuren, G. J., Melief, C. J. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704672104 · Cited by 217
Self-citationSchlecker, E., Fiegler, N., Arnold, A., Altevogt, P., Rose-John, S., Moldenhauer, G., Sucker, A., Paschen, A., von Strandmann, E. P., Textor, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3017 · Cited by 216
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses
Welters, M. J., van der Sluis, T. C., van Meir, H., Loof, N. M., van Ham, V. J., van Duikeren, S., Santegoets, S. J., Arens, R., de Kam, M. L., Cohen, A. F., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8307 · Cited by 216
Self-citationHLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+T lymphocytes
Gooden, M., Lampen, M., Jordanova, E. S., Leffers, N., Trimbos, J. B., van der Burg, S. H., Nijman, H., & van Hall, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100354108 · Cited by 215
Self-citationFourcade, J., Sun, Z., Pagliano, O., Chauvin, J.-M., Sander, C., Janjic, B., Tarhini, A. A., Tawbi, H. A., Kirkwood, J. M., Moschos, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2908 · Cited by 209
Agarwal, P., Raghavan, A., Nandiwada, S. L., Curtsinger, J. M., Bohjanen, P. R., Mueller, D. L., & Mescher, M. F. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900592 · Cited by 203
Bonertz, A., Weitz, J., Pietsch, D.-H. K., Rahbari, N. N., Schlude, C., Ge, Y., Juenger, S., Vlodavsky, I., Khazaie, K., Jaeger, D., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39608 · Cited by 200
Dijkgraaf, E. M., Santegoets, S. J. A. M., Reyners, A. K. L., Goedemans, R., Wouters, M. C. A., Kenter, G. G., van Erkel, A. R., van Poelgeest, M. I. E., Nijman, H. W., van der Hoeven, J. J. M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv309 · Cited by 197
Self-citationKhan, A. N. H., Gregorie, C. J., & Tomasi, T. B. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0402-4 · Cited by 197
van Poelgeest, M. I. E., Welters, M. J. P., van Esch, E. M. G., Stynenbosch, L. F. M., Kerpershoek, G., van Persijn van Meerten, E. L., van den Hende, M., Löwik, M. J. G., Berends-van der Meer, D. M. A., Fathers, L. M., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-88 · Cited by 193
Self-citationSchuurhuis, D. H., Laban, S., Toes, R. E. M., Ricciardi-Castagnoli, P., Kleijmeer, M. J., van der Voort, E. I. H., Rea, D., Offringa, R., Geuze, H. J., Melief, C. J. M., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.1.145 · Cited by 192
Self-citationPredina, J., Eruslanov, E., Judy, B., Kapoor, V., Cheng, G., Wang, L.-C., Sun, J., Moon, E. K., Fridlender, Z. G., Albelda, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211850110 · Cited by 188
de Vries, I. J. M., Bernsen, M. R., Lesterhuis, W. J., Scharenborg, N. M., Strijk, S. P., Gerritsen, M.-J. P., Ruiter, D. J., Figdor, C. G., Punt, C. J. A., & Adema, G. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.478 · Cited by 188
Hypoxia-Inducible miR-210 Regulates the Susceptibility of Tumor Cells to Lysis by Cytotoxic T Cells
Noman, M. Z., Buart, S., Romero, P., Ketari, S., Janji, B., Mari, B., Mami-Chouaib, F., & Chouaib, S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1383 · Cited by 188
Demotte, N., Stroobant, V., Courtoy, P. J., Van Der Smissen, P., Colau, D., Luescher, I. F., Hivroz, C., Nicaise, J., Squifflet, J.-L., Mourad, M., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.01.011 · Cited by 185
Epigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors
Setiadi, A. F., Omilusik, K., David, M. D., Seipp, R. P., Hartikainen, J., Gopaul, R., Choi, K. B., & Jefferies, W. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5270 · Cited by 184
Khan, S., Bijker, M. S., Weterings, J. J., Tanke, H. J., Adema, G. J., van Hall, T., Drijfhout, J. W., Melief, C. J. M., Overkleeft, H. S., van der Marel, G. A., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701705200 · Cited by 175
Self-citationMittendorf, E. A., Clifton, G. T., Holmes, J. P., Clive, K. S., Patil, R., Benavides, L. C., Gates, J. D., Sears, A. K., Stojadinovic, A., Ponniah, S., et al. (2012) · Cancer · doi:10.1002/cncr.26574 · Cited by 172
Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma
Ladányi, A. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12371 · Cited by 168
van Poelgeest, M. I. E., Welters, M. J. P., Vermeij, R., Stynenbosch, L. F. M., Loof, N. M., Berends-van der Meer, D. M. A., Löwik, M. J. G., Hamming, I. L. E., van Esch, E. M. G., Hellebrekers, B. W. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2594 · Cited by 167
Self-citationBartoszewski, R., Brewer, J. W., Rab, A., Crossman, D. K., Bartoszewska, S., Kapoor, N., Fuller, C. M., Collawn, J. F., & Bebők, Z. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.304956 · Cited by 163
Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity
Germain, C., Gnjatic, S., & Dieu-Nosjean, M.-C. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00067 · Cited by 161
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants
van Hall, T., Wolpert, E. Z., van Veelen, P., Laban, S., van der Veer, M., Roseboom, M., Bres, S., Grufman, P., de Ru, A., Meiring, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1381 · Cited by 160
Self-citationImmune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma
Campo, A. B., Kyte, J. A., Carretero, J., Zinchencko, S., Méndez, R., González‐Aseguinolaza, G., Ruiz‐Cabello, F., Aamdal, S., Gaudernack, G., Garrido, F., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28338 · Cited by 159
Tseng, C.-W., Hung, C.-F., Alvarez, R. D., Trimble, C., Huh, W. K., Kim, D., Chuang, C.-M., Lin, C.-T., Tsai, Y.-C., He, L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0037 · Cited by 158
Targeting Tumor-Infiltrating Macrophages to Combat Cancer
Panni, R. Z., Linehan, D. C., & DeNardo, D. G. (2013) · Immunotherapy · doi:10.2217/imt.13.102 · Cited by 155
Wong, S. B. J., Bos, R., & Sherman, L. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3122 · Cited by 153
van Montfoort, N., Camps, M. G. M., Khan, S., Filippov, D. V., Weterings, J. J., Griffith, J. M., Geuze, H. J., van Hall, T., Verbeek, J. S., Melief, C. J. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900969106 · Cited by 151
Self-citationPilon‐Thomas, S., Mackay, A., Vohra, N. A., & Mulé, J. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904114 · Cited by 150
Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells
Alizadeh, D., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0301 · Cited by 149
Georgopoulos, N. T., Proffitt, J. L., & Blair, G. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203860 · Cited by 148
Morse, M. A., Niedzwiecki, D., Marshall, J. L., Garrett, C. H., Chang, D. Z., Aklilu, M., Crocenzi, T. S., Cole, D. J., Dessureault, S., Hobeika, A. C., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318292919e · Cited by 142
Supramolecular peptide vaccines: tuning adaptive immunity
Wen, Y., & Collier, J. H. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.06.007 · Cited by 141
Steding, C. E., Wu, S.-T., Zhang, Y.-P., Jeng, M., Elzey, B. D., & Kao, C. H. (2011) · Immunology · doi:10.1111/j.1365-2567.2011.03429.x · Cited by 134
van Steenwijk, P. J. D. V., Ramwadhdoebé, T. H., Goedemans, R., Doorduijn, E. M., van Ham, J. J., Gorter, A., van Hall, T., Kuijjer, M. L., van Poelgeest, M. I. E., van der Burg, S. H., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28309 · Cited by 131
Tumor Infiltrating T Lymphocytes in Colorectal Cancer
Koch, M., Beckhove, P., den Winkel, J. O., Autenrieth, D., Wagner, P., Nummer, D., Specht, S., Antolovic, D., Galindo, L., Schmitz-Winnenthal, F. H., et al. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000247058.43243.7b · Cited by 131
Carretero, R., Romero, J. M., Ruiz‐Cabello, F., Maleno, I., Rodriguez, F., Camacho, F. M., Real, L. M., Garrido, F., & Cabrera, T. (2008) · Immunogenetics · doi:10.1007/s00251-008-0303-5 · Cited by 128
Engelhard, V. H., Bullock, T. N. J., Colella, T. A., Sheasley-O’Neill, S. L., & Mullins, D. W. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18812.x · Cited by 128
Rapoport, A. P., Aqui, N. A., Stadtmauer, E. A., Vogl, D. T., Xu, Y. Y., Kalos, M. D., Cai, L., Fang, H., Weiss, B. M., Badros, A. Z., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2817 · Cited by 123
Dendritic Cells in Cancer Immunotherapy Clinical Trials: Are We Making Progress?
Butterfield, L. H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00454 · Cited by 123
Natali, P. G., Giacomini, P., Bigotti, A., Imai, K., Nicotra, M., Ng, A., & Ferrone, S. (1983) · PubMed · Cited by 122
van der Burg, S. H., Bijker, M. S., Welters, M. J. P., Offringa, R., & Melief, C. J. M. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.11.003 · Cited by 120
Self-citationSikora, A. G., Jaffarzad, N., Hailemichael, Y., Gelbard, A. H., Stonier, S. W., Schluns, K. S., Frasca, L., Lou, Y., Liu, C., Andersson, H. A., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802982 · Cited by 118
Tumor‐specific CD 4+ T cells maintain effector and memory tumor‐specific CD 8+ T cells
Church, S., Jensen, S. M., Antony, P. A., Restifo, N. P., & Fox, B. A. (2013) · European Journal of Immunology · doi:10.1002/eji.201343718 · Cited by 115
Kleinovink, J. W., van Driel, P. B., Snoeks, T. J. A., Prokopi, N., Fransen, M. F., Cruz, L. J., Mezzanotte, L., Chan, A. B., Löwik, C. W. G. M., & OSSENDORP, F. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0515 · Cited by 115
Self-citationQian, D. Z., Rademacher, B. L. S., Pittsenbarger, J., Huang, C., Myrthue, A., Higano, C. S., Garzotto, M. G., Nelson, P. S., & Beer, T. M. (2009) · The Prostate · doi:10.1002/pros.21077 · Cited by 114
Chemotherapy enhances vaccine‐induced antitumor immunity in melanoma patients
Nisticò, P., Capone, I., Palermo, B., Bello, D. D., Ferraresi, V., Moschella, F., Aricò, E., Valentini, M., Bracci, L., Cognetti, F., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23886 · Cited by 105
Turning tumors into vaccines: co-opting the innate immune system.
van den Boorn, J. G., & Hartmann, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.011 · Cited by 104
Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates
Zom, G. G., Khan, S., Britten, C. M., Sommandas, V., Camps, M. G. M., Loof, N. M., Budden, C. F., Meeuwenoord, N. J., Filippov, D. V., van der Marel, G. A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0223 · Cited by 104
Self-citationKang, T. H., Mao, C.-P., Lee, S. Y., Chen, A. J., Lee, J., Kim, T. W., Alvarez, R. D., Roden, R. B. S., Pardoll, D. M., Hung, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4241 · Cited by 104
der Most, R. G. V., Currie, A. J., Cleaver, A. L., Salmons, J., Nowak, A. K., Mahendran, S., Larma, I., Prosser, A., Robinson, B. W. S., Smyth, M. J., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006982 · Cited by 101
Fruci, D., Giacomini, P., Nicotra, M. R., Forloni, M., Fraioli, R., Saveanu, L., Endert, P. V., & Natali, P. G. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21454 · Cited by 99
Zhang, H., Hong, H. Y., Li, D., Ma, S., Di, Y., Stoten, A., Haig, N. A., di Gleria, K., Yu, Z., Xu, X., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809456200 · Cited by 95
Nishida, S., Koido, S., Takeda, Y., Homma, S., Komita, H., Takahara, A., Morita, S., Ito, T., Morimoto, S., Hara, K., et al. (2014) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000020 · Cited by 94
Metastases in Immune-Mediated Dormancy: A New Opportunity for Targeting Cancer
Romero, I., Garrido, F., & Garcia-Lora, A. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2406 · Cited by 92
van der Sluis, T. C., van Duikeren, S., Huppelschoten, S., Jordanova, E. S., Nejad, E. B., Sloots, A., Boon, L., Smit, V. T. H. B. M., Welters, M. J. P., OSSENDORP, F. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2142 · Cited by 92
Self-citationSeliger, B., Harders, C., Lohmann, S., Momburg, F., Urlinger, S., Tampé, R., & Huber, C. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01<122::aid-immu122>3.0.co;2-f · Cited by 91
Piersma, S. J., Welters, M. J. P., van der Hulst, J. M., Kloth, J. N., Kwappenberg, K. M. C., Trimbos, B. J. B. M. Z., Melief, C. J. M., Hellebrekers, B. W. J., Fleuren, G. J., Kenter, G. G., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23162 · Cited by 87
Self-citationMasuzawa, T., Fujiwara, Y., Okada, K., NAKAMURA, A., Takiguchi, S., Nakajima, K., Miyata, H., Yamasaki, M., Kurokawa, Y., Osawa, R., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1573 · Cited by 87
Strategies to counteract MHC-I defects in tumors
Lampen, M. H., & van Hall, T. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.12.005 · Cited by 85
van Steenwijk, P. J. D. V., Heusinkveld, M., Ramwadhdoebé, T. H., Löwik, M. J. G., van der Hulst, J. M., Goedemans, R., Piersma, S. J., Kenter, G. G., & van der Burg, S. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4299 · Cited by 85
TLR Ligand–Peptide Conjugate Vaccines
Zom, G. G., Khan, S., Filippov, D. V., & OSSENDORP, F. A. (2012) · Advances in immunology · doi:10.1016/b978-0-12-396548-6.00007-x · Cited by 85
Self-citationDijkgraaf, E. M., Santegoets, S. J. A. M., Reyners, A. K. L., Goedemans, R., Nijman, H. W., van Poelgeest, M. I. E., van Erkel, A. R., Smit, V. T. H. B. M., Daemen, T., van der Hoeven, J. J. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4772 · Cited by 84
Self-citationPotentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: A single‐arm phase II study
Vermeij, R., Leffers, N., Hoogeboom, B., Hamming, I. L. E., Wolf, R., Reyners, A. K. L., Molmans, B. H. W., Hollema, H., Bart, J., Drijfhout, J. W., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27388 · Cited by 84
Self-citationvan der Sluis, T. C., Sluijter, M., van Duikeren, S., West, B. L., Melief, C. J. M., Arens, R., van der Burg, S. H., & van Hall, T. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0052 · Cited by 84
Self-citationCabrera, T., Lara, E., Romero, J. M., Maleno, I., Real, L. M., Ruiz‐Cabello, F., Valero, P. M., Camacho, F. M., & Garrido, F. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0226-7 · Cited by 83
Rettig, L., Seidenberg, S., Parvanova, I., Samaras, P., Knuth, A., & Pascolo, S. (2011) · International Journal of Cancer · doi:10.1002/ijc.25756 · Cited by 83
Nagarajan, N. A., Gonzãlez, F., & Shastri, N. (2012) · Nature Immunology · doi:10.1038/ni.2282 · Cited by 83
Ibrahim, N. K., Murray, J. L., Zhou, D., Mittendorf, E. A., Sample, D., Tautchin, M., & Miles, D. W. (2013) · Journal of Cancer · doi:10.7150/jca.7028 · Cited by 82
Sawada, Y., Yoshikawa, T., Shimomura, M., Iwama, T., Endo, I., & Nakatsura, T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2737 · Cited by 82
EMT impairs breast carcinoma cell susceptibility to CTL-mediated lysis through autophagy induction
Akalay, I., Janji, B., Hasmim, M., et al. (2013) · Autophagy · doi:10.4161/auto.24728 · Cited by 80
Binder, D. C., Engels, B., Arina, A., Yü, P., Slauch, J. M., Fu, Y., Karrison, T. G., Burnette, B., Idel, C., Zhao, M. D., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0058 · Cited by 79
Tumor-specific regulatory T cells in cancer patients
Piersma, S. J., Welters, M. J. P., & van der Burg, S. H. (2008) · Human Immunology · doi:10.1016/j.humimm.2008.02.005 · Cited by 78
Verdegaal, E. M. E., Visser, M., Ramwadhdoebé, T. H., van der Minne, C. E., van Steijn, J. A. Q. M. J., Kapiteijn, E., Haanen, J. B. A. G., van der Burg, S. H., Nortier, J. W. R., & Osanto, S. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1004-8 · Cited by 77
Peng, S., Lyford-Pike, S., Akpeng, B., Wu, A. A., Hung, C., Hannaman, D., Saunders, J. R., Wu, T. ‐., & Pai, S. I. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1322-5 · Cited by 77
Suzuki, N., Hazama, S., Ueno, T., Matsui, H., Shindo, Y., Iida, M., Yoshimura, K., Yoshino, S., Takeda, K., & Oka, M. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000012 · Cited by 76
Pedersen, S. R., Sørensen, M. R., Buus, S., Christensen, J. P., & Thomsen, A. R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300555 · Cited by 76
Cariani, E., Pilli, M., Zerbini, A., Rota, C., Olivani, A., Pelosi, G., Schianchi, C., Soliani, P., Campanini, N., Silini, E. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032493 · Cited by 75
Karbach, J., Neumann, A., Atmaca, A., Wahle, C., Brand, K., von Boehmer, L., Knuth, A. K., Bender, A., Ritter, G., Old, L. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1811 · Cited by 75
Charni, S., de Bettignies, G., Rathore, M. G., Aguiló, J. I., van den Elsen, P. J., Haouzi, D., Hipskind, R. A., Enríquez, J. A., Sánchez‐Beato, M., Pardo, J., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001250 · Cited by 71
Novel insights into the molecular mechanisms of HLA class I abnormalities
Seliger, B. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1153-9 · Cited by 71
Palermo, B., Bello, D. D., Sottini, A., Serana, F., Ghidini, C., Gualtieri, N., Ferraresi, V., Catricalà, C., Belardelli, F., Proietti, E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1326 · Cited by 70
Bae, S. H., Park, Y.-J., Park, J.-B., Choi, Y. S., Kim, M. S., & Sin, J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1838 · Cited by 70
Vaccines for Cancer Prevention: A Practical and Feasible Approach to the Cancer Epidemic
Finn, O. J. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0110 · Cited by 69
van Steenwijk, P. J. D. V., van Poelgeest, M. I. E., Ramwadhdoebé, T. H., Löwik, M. J. G., der Meer, D. M. A. B.-V., van der Minne, C. E., Loof, N. M., Stynenbosch, L. F. M., Fathers, L. M., Valentijn, A. R. P. M., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1499-2 · Cited by 68
Self-citationZeestraten, E. C. M., Speetjens, F. M., Welters, M. J. P., Saadatmand, S., Stynenbosch, L. F. M., Jongen, R., Kapiteijn, E., Gelderblom, H. A. J., Nijman, H. W., Valentijn, A. R. P. M., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27819 · Cited by 61
Self-citationBos, R., van Duikeren, S., van Hall, T., Kaaijk, P., Taubert, R., Kyewski, B., Klein, L., Melief, C. J. M., & Offringa, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0666 · Cited by 60
Self-citation
Cited by
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Self-citationSaxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Self-citationEngineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Targeting drugs to tumours using cell membrane-coated nanoparticles
Fang, R. H., Gao, W., & Zhang, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00699-x · Cited by 980
Metadata
- Authors
- van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M.
- Venue
- Nature Reviews Cancer
- Published
- 2016-03-11
- Volume
- 16
- Issue
- 4
- Pages
- 219-233
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2295202170
- Cited by
- 709
- References
- 240
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.